Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2002

01-12-2002 | Commentary

Estrogen–progestin replacement therapy: regulatory action needed

Authors: Malcolm C Pike, Ronald K Ross

Published in: Breast Cancer Research | Issue 6/2002

Login to get access

Abstract

It is now established that the most commonly prescribed estrogen–progestin replacement therapy regimen significantly increases breast cancer risk. What are the risks associated with other regimens? Studies with breast cancer as the outcome cannot answer these questions in the right timeframe. It is incumbent on us to agree that some intermediate marker of risk must be used to show the probable effect of a regimen. We should then act as if the effect on the marker is a quantitative guide to the probable effect on breast cancer risk. Regulatory authorities need to require such studies on all current regimens.
Literature
1.
Schairer C: Progesterone receptors – animal models and cell signalling in breast cancer: implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Res. 2002, 4: 244-248. 10.1186/bcr540.CrossRefPubMedPubMedCentral
2.
Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRef
3.
Henderson BE, Pike MC, Ross RK, Mack TM, Lobo RA: Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril. 1988, 49 (suppl): 9-15.
4.
Key TJA, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988, 24: 29-43. 10.1016/0277-5379(88)90173-3.CrossRefPubMed
5.
Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C: Combined oestrogen-progestogen replacement therapy and breast cancer risk [letter]. Lancet. 1992, 340: 1044-10.1016/0140-6736(92)93064-T.CrossRefPubMed
6.
Shoupe D, Meme D, Mezrow G, Lobo RA: Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Med. 1991, 325: 1811-1812.CrossRefPubMed
7.
Varila E, Wahlstrom T, Rauramo I: A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril. 2001, 76: 969-973. 10.1016/S0015-0282(01)02846-1.CrossRefPubMed
8.
Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV: Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes. Fertil Steril. 1994, 62: 485-490.CrossRefPubMed
9.
Fanchin R, de Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R: Transvaginal administration of progesterone. Obstet Gynecol. 1997, 90: 396-401. 10.1016/S0029-7844(97)00270-6.CrossRefPubMed
10.
Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR: Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol. 1994, 83: 693-700.PubMed
11.
Williams DB, Voigt BJ, Yao SF, Schoenfeld MJ, Judd HL: Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol. 1994, 84: 787-793.PubMed
12.
Pike MC, Ross RK: Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000, 65: 659-664. 10.1016/S0039-128X(00)00122-7.CrossRefPubMed
13.
Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskaas C, Bush T, Barrett-Connor E: Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Ann Intern Med. 1999, 130: 262-269.CrossRefPubMed
Metadata
Title
Estrogen–progestin replacement therapy: regulatory action needed
Authors
Malcolm C Pike
Ronald K Ross
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr550

Other articles of this Issue 6/2002

Breast Cancer Research 6/2002 Go to the issue

Research article

No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer

Research article

Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer

Research article

Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990–1999

Viewpoint

Mutations in DNA damage response genes and breast cancer susceptibility

Review

Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer

Commentary

Prolactin signaling and Stat5: going their own separate ways?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits